Clinical Trial

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 23, 2023 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic hepatocellular carcinoma (HCC). The main question to answer is: Whether combing SBRT with immunotherapy and targeted therapy could prolong PFS. Participants will receive SBRT to all visible lesions and concurrent systemic immunotherapy and targeted therapy.
Trial Details
NCT Number NCT05917431
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Enrollment 39 participants
Start Date 2023-06
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-06-23